These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31679948)

  • 21. Immunotherapeutic Approaches to the Management of Head and Neck Cancer.
    Nan X; Gold KA; Cohen E
    Oncology (Williston Park); 2018 Dec; 32(12):617-9, 625-6. PubMed ID: 30632130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.
    Rothschild U; Muller L; Lechner A; Schlösser HA; Beutner D; Läubli H; Zippelius A; Rothschild SI
    Swiss Med Wkly; 2018; 148():w14625. PubMed ID: 29756633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
    Kondo N; Tsukuda M; Taguchi T; Nakazaki K; Sakakibara A; Takahashi H; Toth G; Nishimura G
    Cancer Sci; 2011 Sep; 102(9):1717-23. PubMed ID: 21631644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Not Available].
    Reverdy T; Gau M; Karabajakian A; Neidhardt EM; Fayette J
    Bull Cancer; 2018 Dec; 105 Suppl 1():S35-S42. PubMed ID: 30595197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Cetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck.
    Li JZ; Zheng JW; Zhang ZY
    Shanghai Kou Qiang Yi Xue; 2008 Feb; 17(1):1-5. PubMed ID: 18360658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cetuximab in the treatment of squamous cell carcinoma of the head and neck.
    Specenier P; Vermorken JB
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):511-24. PubMed ID: 21504318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and preclinical investigation of
    Shah SQ; Gul-E-Raana
    Mol Biol Rep; 2019 Apr; 46(2):1675-1682. PubMed ID: 30680596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
    Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
    J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-1 antibodies in head-and-neck cancer.
    Wollenberg B
    Lancet; 2019 Jan; 393(10167):108-109. PubMed ID: 30509741
    [No Abstract]   [Full Text] [Related]  

  • 30. [Immuno-oncology of head and neck tumors].
    Kasper S; Hussain T; Virchow I; Stuschke M; Lang S
    HNO; 2019 Mar; 67(3):221-235. PubMed ID: 30635676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.
    Rampias T; Giagini A; Siolos S; Matsuzaki H; Sasaki C; Scorilas A; Psyrri A
    Clin Cancer Res; 2014 Jun; 20(11):2933-46. PubMed ID: 24696319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular response to cetuximab in PTEN-silenced head and neck squamous cell carcinoma cell line.
    Mriouah J; Boura C; Pinel S; Chretien AS; Fifre A; Merlin JL; Faivre B
    Int J Oncol; 2010 Dec; 37(6):1555-63. PubMed ID: 21042725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer.
    Bossi P; Kornek G; Lanzetta G; Rozzi A; Füreder T; Locati L; Licitra L
    Head Neck; 2013 Oct; 35(10):1471-4. PubMed ID: 23042567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy in head and neck cancer: evidence and perspectives.
    Tosoni A; Franceschi E; Pasquini E; Lanese A; Donini E; Foschini MP; Dall'Olio D; Brandes AA
    Immunotherapy; 2017 Dec; 9(16):1351-1358. PubMed ID: 29185392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer.
    Pointreau Y; Azzopardi N; Ternant D; Calais G; Paintaud G
    Ther Drug Monit; 2016 Oct; 38(5):567-72. PubMed ID: 27631463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
    Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Experimental study on cetuximab and dendritic cells killing head and neck squamous cell].
    Zhang M; Wang X
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Aug; 28(15):1133-6. PubMed ID: 25322601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy of head and neck squamous cell carcinoma (HNSCC). Immune checkpoint blockade.
    Przybylski K; Majchrzak E; Weselik L; Golusiński W
    Otolaryngol Pol; 2018 Sep; 72(6):10-16. PubMed ID: 30647199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.